AHSG and chronic kidney disease: Additionally, imbalances in circulating biomarkers including intact parathyroid hormone (iPTH), fibroblast growth factor 23 (FGF 23), and sclerostin that promotes or Fetuin-A that inhibits VC processes have emerged as potential markers of VC susceptibility of CKD patients [4,6,7].